Ono Pharma and Aitia Announce Collaboration to Identify Novel Drug Targets in Neurological Diseases
Aitia’s causal AI-based Gemini Digital Twin Platform will be used to derisk the discovery and development of Ono’s new
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
Aitia’s causal AI-based Gemini Digital Twin Platform will be used to derisk the discovery and development of Ono’s new pipeline
programs
CAMBRIDGE, MA, UNITED STATES, September 1, 2026 /EINPresswire.com/ — Aitia, whose causal AI-powered Gemini Digital Twin Platform uniquely uncovers complex
disease biology and applies that knowledge to pharmaceutical discovery and
development, and Ono Pharmaceutical Co., Ltd (Headquarters: Osaka, Japan; President
and COO: Toichi Takino; “Ono”) today announced a collaboration to bring their respective
strengths together to discover novel neurological disease targets and develop effective new
therapeutics.
“A critical reason we have so few effective treatments for most neurological diseases is our
ongoing, fundamental lack of knowledge of their complex biological causes, ” said Colin
Hill, CEO and co-founder of Aitia. “We believe that working with Ono’s world-class medical
and pharmaceutical development experts to build comprehensive in silico Gemini Digital
Twins of neurological disease will help uncover new validated drug targets and drive
rational discovery approaches that lead to effective interventions.”
“Ono has a long and proud history of developing pharmaceuticals for many significant
unmet medical needs,” said Seishi Katsumata, Corporate Officer/Executive Vice President,
Discovery & Research of Ono. “We are committed to applying that same expertise and
passion to the treatment of devastating neurological diseases, and we believe that
collaborating closely with Aitia’s researchers to deeply understand the underlying complex
biology will best accelerate successful therapeutic discovery and development.”
Fintan R. Steele, PhD
Aitia
+1 617-816-9834
fsteele@aitia.com
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
